SH
SHINIL PHARMACEUTICAL CO., LTD.
012790 | KO
Overview
Corporate Details
- ISIN(s):
- KR7012790002
- LEI:
- Country:
- South Korea
- Address:
- 충북 충주시 앙성면 본평리 산 5-1, 충주시
- Website:
- https://shinilpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.1 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 841.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 876.9 KB | ||
| 2025-03-24 00:00 |
AGM Information
정기주주총회결과
|
Korean | 22.2 KB | ||
| 2025-03-14 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 17.2 KB | ||
| 2025-03-14 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 1.0 MB | ||
| 2025-03-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.8 KB | ||
| 2025-03-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 87.0 KB | ||
| 2025-03-04 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 9.3 KB | ||
| 2024-12-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2024-12-16 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 5.6 KB | ||
| 2024-11-14 00:00 |
Quarterly Report
분기보고서 (2024.09)
|
Korean | 740.8 KB | ||
| 2024-08-09 00:00 |
Interim / Quarterly Report
반기보고서 (2024.06)
|
Korean | 738.9 KB | ||
| 2024-06-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 20.9 KB | ||
| 2024-05-16 00:00 |
Quarterly Report
분기보고서 (2024.03)
|
Korean | 788.8 KB |
Automate Your Workflow. Get a real-time feed of all SHINIL PHARMACEUTICAL CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SHINIL PHARMACEUTICAL CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SHINIL PHARMACEUTICAL CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing therapies for neurodegenerative diseases that cross the blood-brain barrier.
United States of America
DNLI
United States of America
DNLI
Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.
Germany
DMP
Germany
DMP
Develops OTC skin treatments using a unique delivery technology from freshwater sponges.
United States of America
DRMA
United States of America
DRMA
Develops small molecule genomic medicines to treat serious genetic diseases by modulating genes.
United States of America
DSGN
United States of America
DSGN
Develops biomarker-driven therapeutics and diagnostics for serious diseases with unmet needs.
Germany
DBI
Germany
DBI
Global manufacturer of human/veterinary pharmaceuticals, APIs, and medical ampoules.
Spain
DEVA
Spain
DEVA
Develops & sells genetic DNA test kits for labs in oncology, transplant & reproductive health.
Sweden
DVYSR
Sweden
DVYSR
Developing pharmaceuticals for urological oncology using its proprietary GuaDex technology platform.
Sweden
DEX
Sweden
DEX
Developing a novel protein therapy for acute ischemic stroke and preeclampsia.
United States of America
DMAC
United States of America
DMAC
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
Developing precision immunotherapies to preserve insulin in autoimmune diabetes.
Sweden
DMYD
Sweden
DMYD